• OPEN AN ACCOUNT
Indian Indices
Nifty
25,090.70 122.30
(0.49%)
Sensex
82,248.89 48.55
( 0.06%)
Bank Nifty
56,952.75 669.75
( 1.19%)
Nifty IT
37,031.75 -110.10
( -0.30%)
Global Indices
Nasdaq
44,352.54 -10.66
(-0.02%)
Dow Jones
6,327.21 9.42
(0.15%)
Hang Seng
39,788.57 -112.62
(-0.28%)
Nikkei 225
9,012.99 20.87
(0.23%)
Forex
USD-INR
86.15 0.16
(0.18%)
EUR-INR
100.12 0.38
(0.38%)
GBP-INR
115.49 0.24
(0.21%)
JPY-INR
0.58 0.00
(0.02%)

EQUITY - MARKET SCREENER

IFL Enterprises Ltd
Industry :  Trading
BSE Code
ISIN Demat
Book Value()
540377
INE714U01024
1.0290753
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
N.A
46.5
115.79
EPS(TTM)
Face Value()
Div & Yield %
0.02
1
0
 

Natco Pharma receives seven observations from USFDA Following Inspection at Kothur Facility
Jun 20,2025
In a regulatory filing, the company stated that the USFDA conducted the inspection from 9 June to 19 June 2025. At the conclusion of inspection, the USFDA has issued a Form 483 with seven observations.

Natco Pharma expressed confidence in addressing the observations within the stipulated timeline and reaffirmed its commitment to current Good Manufacturing Practices (cGMP) and the consistent supply of high-quality pharmaceutical products to global markets.

NATCO Pharma, headquartered at Hyderabad, India, develops, manufactures and distributes generic and branded pharmaceuticals, specialty pharmaceuticals, active pharmaceutical ingredients and crop protection products.

The company’s consolidated net profit increased 5.3% to Rs 406.60 crore on a 14.3% jump in revenue from operations to Rs 1,221 crore in Q4 FY25 over Q4 FY24.

The counter shed 0.98% to Rs 872.75 on the BSE.